## immers V

## **TEZSPIRE® ORDER FORM**

## FAX TO: 855.694.4656

PATI	ENT	INFOF	RMAT	ON

PATIENT NAME:	PHONE:		
DATE OF BIRTH: SEX: M	F HEIGHT: WEIGHT: LBS KG		
ALLERGIES:	PREFERRED CLINIC:		
REFERRAL STATUS: NEW REFERRAL	ORDER CHANGE ORDER RENEWAL		
DIAGNOSIS & CLINICAL DOCU	MENTATION		
J45.50 Severe persistent asthma, uncompl	icated		
J45.51 Severe persistent asthma with (acu	te) exacerbation		
DESCRIPTION	N:		
REQ	UIRED DOCUMENTATION		
Insurance List of Medications	Tried & Failed Most Recent History & Physical		
Lab results and/or Pulmonary Function Tests support diagnosis	to		
MEDICATION ORDER	PROVIDER ATTESTATION OF NEED FOR HCP ADMINISTRATION		
Tezspire <sup>®</sup> (tezepelumab) 210mg via subcutaneous injection every 4 weeks	Patient has experienced severe hypersensitivity reactions to Tezspire within the past 6 months and requires administration and direct monitoring by a healthcare professional.		
COMMENTS:	Patient or caregiver are not competent or are physically unable to administer the Tezspire formulation labeled for self-administration.		
✓ REFILL X 12 MONTHS UNLESS OTHERWISE	Patient has history of uncontrolled disease and in the clinical opinion of the ordering provider, it is not advisable to try the self-administered formulation of Tezspire.		
NOTED HERE:	The circumstances and location for self-administration are not adequate for the potential treatment of anaphylaxis.		
	Patient's weight is such that in the clinical opinion of the ordering provider, it is not advisable to try the self-administered formulation of Tezspire.		
In the event of an adverse reaction occurring in the infusion cl	inic, utilize the Immersiv Health adverse reaction protocol.		
PRESCRIBER INFORMATION			
PROVIDER NAME:	NPI #:		
EMAIL:	PHONE: FAX:		
ADDRESS (INCLUDE CITY, STATE, ZIP):			
SUPERVISING PHYSICIAN: (IF APPLICABLE)	CONTACT NAME:		
SIGNATURE:	DATE:		
(NUSTAMPS)	DISPENSE AS WRITTEN		